Get started
BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD)BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD)BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD)

BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD)

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0QNA chart


Full chart

0QNA upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪519.77 M‬CHF
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.05CHF
Net income (FY)
‪10.45 M‬CHF
Revenue (FY)
‪157.63 M‬CHF
Shares float
‪11.12 M‬
Beta (1Y)
1.18

Employees


Employees (FY)
147
Change (1Y)
−7 −4.55%
Revenue / Employee (1Y)
‪1.27 M‬CHF
Net income / Employee (1Y)
‪84.44 K‬CHF

About BASILEA N


Sector
Health Technology
CEO
David Veitch
Headquarters
Allschwil
Website
basilea.com
Founded
2000
ISIN
CH0011432447
FIGI
BBG00NRVXXQ4
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. Its products include antifungals and antibiotics. The company was founded on October 17, 2000, and is headquartered in Allschwil, Switzerland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

0QNA news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0QNA is 43.40 CHF — it has increased by 2.23% in the past 24 hours. Watch BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) stocks are traded under the ticker 0QNA.
0QNA stock has fallen by −0.91% compared to the previous week, the month change is a −4.07% fall, over the last year BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) has showed a 17.30% increase.
We've gathered analysts' opinions on BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) future price: according to them, 0QNA price has a max estimate of 100.00 CHF and a min estimate of 52.00 CHF. Watch 0QNA chart and read a more detailed BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) stock forecast: see what analysts think of BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) and suggest that you do with its stocks.
0QNA reached its all-time high on Feb 12, 2021 with the price of 61.95 CHF, and its all-time low was 29.50 CHF and was reached on Mar 16, 2020. View more price dynamics on 0QNA chart.
See other stocks reaching their highest and lowest prices.
0QNA stock is 1.15% volatile and has beta coefficient of 1.18. Track BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) stock price on the chart and check out the list of the most volatile stocks — is BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) there?
Today BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) has the market capitalization of ‪523.63 M‬, it has decreased by −1.58% over the last week.
Yes, you can track BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) financials in yearly and quarterly reports right on TradingView.
BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) is going to release the next earnings report on Feb 18, 2025. Keep track of upcoming events with our Earnings Calendar.
0QNA earnings for the last half-year are 1.61 CHF per share, whereas the estimation was 1.17 CHF, resulting in a 37.61% surprise. The estimated earnings for the next half-year are 2.48 CHF per share. See more details about BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) earnings.
BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) revenue for the last half-year amounts to ‪76.30 M‬ CHF, despite the estimated figure of ‪106.10 M‬ CHF. In the next half-year revenue is expected to reach ‪123.50 M‬ CHF.
0QNA net income for the last half-year is ‪20.74 M‬ CHF, while the previous report showed ‪−21.39 M‬ CHF of net income which accounts for 196.95% change. Track more BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) financial stats to get the full picture.
No, 0QNA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 4, 2024, the company has 147.00 employees. See our rating of the largest employees — is BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) EBITDA is ‪−4.99 M‬ CHF, and current EBITDA margin is 14.39%. See more stats in BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) financial statements.
Like other stocks, 0QNA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) stock shows the buy signal. See more of BASILEA PHARMACEUTICA AG ALLSCHWIL CHF1 (REGD) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.